Post-exposure immunotherapy for two ebolaviruses and Marburg virus in nonhuman primates
Current experimental monoclonal antibodies (mAbs) for Ebola virus (EBOV) post-exposure immunotherapy are ineffective against Sudan (SUDV) or Marburg virus (MARV). Here, authors develop cocktails of mAbs that protect nonhuman primates against EBOV, SUDV, and MARV infection when given four days post i...
Guardado en:
Autores principales: | Jennifer M. Brannan, Shihua He, Katie A. Howell, Laura I. Prugar, Wenjun Zhu, Hong Vu, Sergey Shulenin, Shweta Kailasan, Henna Raina, Gary Wong, Md Niaz Rahim, Logan Banadyga, Kevin Tierney, Xuelian Zhao, Yuxing Li, Frederick W. Holtsberg, John M. Dye, Xiangguo Qiu, M. Javad Aman |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b99aa7a0e5ce4018ab41eac4e31287f3 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Atypical Ebola Virus Disease in a Nonhuman Primate following Monoclonal Antibody Treatment Is Associated with Glycoprotein Mutations within the Fusion Loop
por: Logan Banadyga, et al.
Publicado: (2021) -
Structural basis for broad neutralization of ebolaviruses by an antibody targeting the glycoprotein fusion loop
por: Benjamin M. Janus, et al.
Publicado: (2018) -
Deep-sequencing of Marburg virus genome during sequential mouse passaging and cell-culture adaptation reveals extensive changes over time
por: Haiyan Wei, et al.
Publicado: (2017) -
Discovery of an ebolavirus-like filovirus in europe.
por: Ana Negredo, et al.
Publicado: (2011) -
Risks Posed by Reston, the Forgotten Ebolavirus
por: Diego Cantoni, et al.
Publicado: (2016)